An overview of our pipeline of product candidates is shown in the table below. The sites of two mutations defined as canonical mutations are indicated. The formatting of these constitutive dimers is essential for oncogenicity. Bioluminescence imaging in mice expressing intracranial GBM6 patient derived tumors. Tumor regression in mouse models has been observed. Some long-term preclinical testing may continue after the IND is submitted. Further, under PDUFA, as amended, each NDA must be accompanied by a user fee. We continue to evaluate what effect, if any, these rules will have on our business. On May 30, 2018, the Right to Try Act was signed into law. As a result, increasingly high barriers are being erected to the entry of new products. However, overall related timelines will be defined by the Clinical Trials Regulation. Our website address is https://www.blackdiamondtherapeutics.com. Investing in our common stock involves a high degree of risk. We are very early in our development efforts. We rely on third parties for the manufacture of our product candidates. Most of our product candidates are still in preclinical development. We are still in the early stages of development of our product candidates. Orphan drug designation must be requested before submitting an NDA. Designation as a breakthrough therapy is within the discretion of the FDA. We may also submit marketing applications in other countries. It is unclear whether the ACA will be overturned, repealed, replaced, or further amended. Average review times at the agency have fluctuated in recent years as a result. We cannot eliminate the risk of contamination or injury from these materials. Therefore, we may miss potential opportunities to establish our patent position. These lawsuits may consume our time and other resources even if we are successful. Litigation or arbitration may be necessary to defend against these claims. As of December 31, 2020, we had 69 full-time employees.